John B. Henneman III, Director at Aprea Therapeutics, Inc. (APRE), bought 5,000 shares at $15.00 ($75K) on 2019-10-07, disclosed to the SEC on 2019-10-07.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| APRE | BUY | 2024-03-14 | $100K | — | Filing → |
| RCM | SELL | 2023-08-09 | $1.7M | — | Filing → |
| ANIK | BUY | 2021-05-20 | $86K | — | Filing → |